View in EDS

PCSK9: A new participant in lipophagy in regulating atherosclerosis?

Saved in:
Bibliographic Details
Title: PCSK9: A new participant in lipophagy in regulating atherosclerosis?
Authors: Xiao, Jun1 (AUTHOR), Deng, Yi-Min1 (AUTHOR), Liu, Xiang-Rui1 (AUTHOR), Cao, Jian-Ping1 (AUTHOR), Zhou, Min1 (AUTHOR), Tang, Ya-Ling1 (AUTHOR), Xiong, Wen-Hao1 (AUTHOR), Jiang, Zhi-Sheng1 (AUTHOR), Tang, Zhi-Han1 (AUTHOR) Tangzhihan98@163.com, Liu, Lu-Shan1 (AUTHOR) liuls2000@163.com
Source: Clinica Chimica Acta. Aug2019, Vol. 495, p358-364. 7p.
Subjects: Lipid metabolism, Lysosomes, Low density lipoprotein receptors, Lipoprotein receptors, Atherosclerosis
Abstract: Proprotein convertase subtilisin kexin 9 (PCSK9) regulates lipid metabolism by degrading low-density lipoprotein receptor on the surface of hepatocytes. PCSK9-mediated lipid degradation is associated with lipophagy. Lipophagy is a process by which autophagosomes selectively sequester lipid-droplet-stored lipids and are delivered to lysosomes for degradation. Lipophagy was first discovered in hepatocytes, and its occurrence provides important fundamental insights into how lipid metabolism regulates cellular physiology and pathophysiology. Furthermore, PCSK9 may regulate lipid levels by affecting lipophagy. This review will discuss recent advances by which PCSK9 mediates lipid degradation via the lipophagy pathway and present lipophagy as a potential therapeutic target for atherosclerosis. • Atherosclerosis is a chronic inflammatory disease characterized by lipid accumulation; • Lipophagy plays an important role in the prevention of atherosclerosis by removing excessive lipids; • PCSK9 participates in lipid metabolism through the lipophagy pathway, and thus affects atherosclerosis. [ABSTRACT FROM AUTHOR]
Copyright of Clinica Chimica Acta is the property of Elsevier B.V. and its content may not be copied or emailed to multiple sites without the copyright holder's express written permission. Additionally, content may not be used with any artificial intelligence tools or machine learning technologies. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Engineering Source
Description
Abstract:Proprotein convertase subtilisin kexin 9 (PCSK9) regulates lipid metabolism by degrading low-density lipoprotein receptor on the surface of hepatocytes. PCSK9-mediated lipid degradation is associated with lipophagy. Lipophagy is a process by which autophagosomes selectively sequester lipid-droplet-stored lipids and are delivered to lysosomes for degradation. Lipophagy was first discovered in hepatocytes, and its occurrence provides important fundamental insights into how lipid metabolism regulates cellular physiology and pathophysiology. Furthermore, PCSK9 may regulate lipid levels by affecting lipophagy. This review will discuss recent advances by which PCSK9 mediates lipid degradation via the lipophagy pathway and present lipophagy as a potential therapeutic target for atherosclerosis. • Atherosclerosis is a chronic inflammatory disease characterized by lipid accumulation; • Lipophagy plays an important role in the prevention of atherosclerosis by removing excessive lipids; • PCSK9 participates in lipid metabolism through the lipophagy pathway, and thus affects atherosclerosis. [ABSTRACT FROM AUTHOR]
ISSN:00098981
DOI:10.1016/j.cca.2019.05.005